TMCnet News
INVESTOR ALERT: Lundin Law PC Announces an Ongoing Investigation of INSYS Therapeutics, Inc. and Urges Investors with Losses to Contact the FirmLundin Law PC announces it is investigating claims against INSYS Therapeutics, Inc. ("INSYS" or the "Company") (Nasdaq: INSY) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by INSYS were false and misleading and/or failed to disclose material information regarding the Company's financial performance. To participate in this class action lawsuit, pleasecontact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at [email protected]. The investigation will focus on whether the Company made materially false and misleading statements and/or failed to disclose that: (1) INSYS Therapeutics was engaged in the illegal and improper off-labeling marketing of Subsys; and (2) certain INSYS Therapeutics employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys. No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160209006584/en/ |
